Aptargroup Stock Earnings Reports

Aptar reported Q1 2026 results largely in line with expectations. Reported sales rose 11% while core sales (adjusted for currency and acquisitions) were flat year‑over‑year. Adjusted EBITDA was $189 million (up 3%) and adjusted EPS was $1.19 (down ~8% on a comparable FX basis). Key headwinds were an anticipated destocking in emergency medicine (primarily naloxone/Narcan) which reduced pharma core sales by ~3% in Q1 and is expected to total an approximate $65 million adverse impact for full‑year 2026 (about two‑thirds of that impact in H1). Outside that emergency medicine destock, pharma demand remains healthy with strength in injectables (notably elastomeric components for GLP‑1 biologics), systemic nasal drug delivery, ophthalmic dispensing, and consumer healthcare. Beauty posted modest volume/mix gains, led by prestige fragrance pumps, while closures volumes improved but revenue was affected by lower resin pass‑through pricing and operational/ weather‑related disruptions that compressed margins. Consolidated gross margin contracted ~210 basis points; adjusted EBITDA margin declined to 19.2% driven by mix and operational issues in beauty and closures. Free cash flow more than doubled to $53 million; the company repurchased $100 million of stock and paid $31 million in dividends. Balance sheet remains strong (cash $223M, net debt ~$1.1B, leverage 1.43x). Management expects Q2 adjusted EPS of $1.32–$1.40, is managing cost pass‑throughs amid elevated input and energy costs related to geopolitical tensions, and anticipates sequential margin recovery and solid growth ex‑emergency medicine as the year progresses. Ongoing litigation with ARS Pharmaceuticals remains in discovery.